HC Wainwright & Co. Maintains Buy on Vigil Neuroscience, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Vigil Neuroscience (NASDAQ:VIGL) but lowers the price target from $24 to $17.
July 19, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Vigil Neuroscience but lowers the price target from $24 to $17.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates tempered expectations for short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100